Advanced and Metastatic Solid Tumors
Inhibrx Biosciences Inc. focuses on oncology programs for adults with advanced or metastatic solid tumors, including broader tumour settings where disease control and progression outcomes are central clinical concerns. Its portfolio includes studies across multiple solid tumor types and treatment combinations.
- Solid tumor oncology
- Metastatic cancer
- Antitumor efficacy
Research activity in this area spans patients with difficult-to-treat malignancies and evaluation of therapeutic approaches intended to address tumour growth and disease progression.
Head and Neck Squamous Cell Carcinoma
The sponsor has active interest in head and neck squamous cell carcinoma, with clinical research centered on recurrent or metastatic disease. This area reflects a focus on immuno-oncology and combination treatment strategies in a high-need solid tumor population.
- Recurrent or metastatic HNSCC
- Immune checkpoint therapy
- Combination oncology regimens
Clinical activity in this indication supports investigation of treatment options for patients with limited therapeutic alternatives in head and neck cancer.
Conventional Chondrosarcoma
Inhibrx Biosciences Inc. is also engaged in research for unresectable or metastatic conventional chondrosarcoma, a rare bone and cartilage cancer with significant unmet medical need. This area highlights its involvement in sarcoma research and treatment development for uncommon malignancies.
- Chondrosarcoma
- Sarcoma oncology
- Rare cancer treatment
The sponsor’s work in this domain is directed toward patients with surgically difficult or disseminated disease.
Sarcomas and Other Unmet-Need Tumors
Beyond individual tumour types, the sponsor funds research in broader sarcoma and rare solid tumor settings, including Ewing sarcoma and gastrointestinal stromal tumor. These studies extend into difficult-to-treat cancers where new anticancer approaches are being explored.
- Ewing sarcoma
- Gastrointestinal stromal tumor
- Colorectal adenocarcinoma
Its clinical research footprint includes combinations with established chemotherapy and immunotherapy backbones across diverse advanced malignancies.
